



Ref: Syn/CS/SE/BM/2026-27/Oct/05

Syngene International Limited

Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560 099, Karnataka, India

T +91 80 6891 9191

CIN: L85110KA1993PLC014937

www.syngeneintl.com

October 27, 2026

To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001	To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051
Scrip Code: 539268	Scrip Symbol: SYNGENE

Sub: Outcome of the Board Meeting

Dear Sir/Madam,

Pursuant to Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015 (“SEBI Listing Regulations”), we wish to inform you that the Board of Directors, at its meeting held today i.e. October 27, 2026, has inter-alia, considered and approved the Un-audited financial results (standalone and consolidated) as per Indian Accounting Standards (Ind-AS) for the quarter and half year ended September 30, 2026. A copy of the unaudited financial results along with the Limited Review Reports is enclosed herewith.

The Board Meeting commenced at 15:15 (IST) and concluded at 18:30 (IST).

The above information will also be made available on the website of the Company at www.syngeneintl.com.

Kindly take the above information on record.

Thanking You

Yours faithfully,

For SYNGENE INTERNATIONAL LIMITED

Digitally signed
by CHETHAN
YOGESH
Date: 2026.10.27
18:53:30 +05'30'

Chethan Yogesh
Company Secretary and Compliance Officer

Encl: a/a

STATEMENT OF UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026							
(Rs. in million, except per share data)							
Sl. No.	Particulars	3 months ended 30 September 2026	Preceding 3 months ended 30 June 2026	Corresponding 3 months ended in the previous year 30 September 2025	Year to date figures for the current period ended 30 September 2026	Year to date figures for the previous period ended 30 September 2025	Previous year ended 31 March 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	a) Revenue from operations	8,327	7,360	9,106	15,687	17,851	37,387
	b) Other Income	280	253	154	533	331	707
	Total Income	8,607	7,613	9,260	16,220	18,182	38,094
2	Expenses						
	a) Cost of chemicals, reagents and consumables consumed	2,030	1,782	2,275	3,812	4,670	9,112
	b) Changes in inventories of finished goods and work-in-progress	(44)	(48)	110	(92)	(109)	74
	c) Employee benefits expense	2,727	2,711	2,855	5,438	5,567	11,490
	d) Finance costs	100	96	132	196	248	488
	e) Depreciation and amortisation expense	1,117	1,122	1,165	2,239	2,277	4,529
	f) Other expenses	1,526	1,506	1,753	3,032	3,498	6,917
	g) Foreign exchange fluctuation loss, net	614	501	118	1,115	166	609
	Total expenses	8,070	7,670	8,408	15,740	16,317	33,219
3	Profit before tax and exceptional items (1-2)	537	(57)	852	480	1,865	4,875
4	Exceptional Items, net gain/ (loss) [refer note 6 & 7]	(67)	(135)	-	(202)	-	(766)
5	Profit before tax (3-4)	470	(192)	852	278	1,865	4,109
6	Tax expense						
	Current tax	94	1	177	95	405	870
	Deferred tax	54	(103)	4	(49)	(78)	72
	Total tax expense	148	(102)	181	46	327	942
7	Profit for the period / year (5-6)	322	(90)	671	232	1,538	3,167
8	Other comprehensive income						
	(A) (i) Items that will not be reclassified to profit or (loss)	(23)	(6)	(54)	(29)	(51)	(63)
	(ii) Income tax relating to items that will not be reclassified to profit or (loss)	3	2	14	5	13	16
	(B) (i) Items that will be reclassified to profit or (loss)	142	478	(1,890)	620	(1,603)	(2,679)
	(ii) Income tax relating to items that will be reclassified to profit or (loss)	(15)	(121)	542	(136)	467	766
	Other comprehensive income for the period / year, net of taxes	107	353	(1,388)	460	(1,174)	(1,960)
9	Total comprehensive income for the period / year (7+8)	429	263	(717)	692	364	1,207
10	Paid-up equity share capital (Face value of Rs.10 each) [refer note 4]	4,037	4,037	4,029	4,037	4,029	4,029
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'						44,362
12	Earnings per share (of Rs.10 each)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	a) Basic	0.80	(0.22)	1.67	0.58	3.82	7.87
	b) Diluted	0.80	(0.22)	1.67	0.58	3.82	7.87
	See accompanying notes to the financial results						

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

CONSOLIDATED STATEMENT OF ASSETS AND LIABILITIES		
	(Rs. in Million)	
Particulars	As at 30 September 2026 (Unaudited)	As at 31 March 2026 (Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	24,475	25,454
Capital work-in-progress [refer note 5]	11,406	10,404
Right-of-use assets	3,639	3,845
Investment property	210	315
Other intangible assets	431	386
Intangible assets under development	47	53
Financial assets		
(i) Investments	2,005	2,863
(ii) Derivative assets	248	317
(iii) Other financial assets	1,946	3,116
Deferred tax assets (net)	930	1,007
Income tax assets (net)	1,548	1,088
Other non-current assets	219	133
Total non-current assets	47,104	48,981
Current assets		
Inventories	1,678	1,413
Financial assets		
(i) Investments	4,093	4,610
(ii) Trade receivables	3,855	5,088
(iii) Cash and cash equivalents	1,199	2,286
(iv) Bank balances other than (iii) above	8	2,021
(v) Derivative assets	26	69
(vi) Other financial assets	6,765	4,247
Other current assets	1,857	1,687
Total current assets	19,481	21,421
Total assets	66,585	70,402
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,037	4,029
Other equity	44,551	44,362
Total equity	48,588	48,391
Liabilities		
Non-current liabilities		
Financial liabilities		
(ii) Lease liabilities	4,193	4,303
(iii) Derivative liabilities	196	488
(iii) Other financial liabilities	2	1
Provisions	-	180
Other non-current liabilities	1,777	1,979
Total non-current liabilities	6,168	6,951
Current liabilities		
Financial liabilities		
(i) Borrowings	672	94
(ii) Lease liabilities	209	187
(iii) Trade payables		
total outstanding dues of micro and small enterprises	604	588
total outstanding dues of creditors other than micro and small enterprises	2,429	2,221
(iv) Derivative liabilities	1,043	1,145
(v) Other financial liabilities	1,282	1,775
Provisions	832	1,144
Current tax liabilities (net)	84	98
Other current liabilities	4,674	7,808
Total current liabilities	11,829	15,060
Total equity and liabilities	66,585	70,402

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

CONSOLIDATED STATEMENT OF CASH FLOWS			
		(Rs. in Million)	
Sl. No.	Particulars	Six months ended 30 September 2026 (Unaudited)	Six months ended 30 September 2025 (Unaudited)
1	Cash flows from operating activities		
	Profit for the year	232	1,538
	<u>Adjustments to reconcile profit after tax to net cash flows:</u>		
	Depreciation and amortisation expense	2,239	2,277
	(Gain)/loss on disposal of property, plant and equipment (net)	(25)	11
	Impairment allowances of doubtful trade receivables	47	(11)
	Bad debts written off	-	278
	Advances to suppliers written off	(7)	-
	Share-based payment expenses (net)	4	216
	Interest expense	196	250
	Unrealised foreign exchange gain	(36)	(21)
	Net gain on sale of current investments	(64)	(46)
	Interest income	(419)	(286)
	Interest on Income tax refund	(51)	-
	Tax expenses	46	327
	Operating profit before working capital changes	2,162	4,533
	Movements in working capital		
	Decrease/ (increase) in inventories	(265)	(338)
	Decrease/ (increase) in trade receivables	1,169	(351)
	Decrease/ (increase) in other financial and other assets	(151)	(1,173)
	Increase/ (decrease) in trade payables, provisions, financial and other liabilities	(3,822)	(2,657)
	Cash generated from/ (used in) operations	(907)	14
	Income taxes paid (net of refunds)	(525)	(465)
	Net cash flow generated from/ (used in) operating activities	(1,432)	(451)
2	Cash flows from investing activities		
	Purchase of property, plant and equipment including investment properties and capital work-in progress	(2,099)	(1,552)
	Proceeds from sale of property plant and equipments	28	1
	Purchase of intangible assets including intangible assets under development	(103)	(117)
	Investment in equity shares	(25)	-
	Investment in bank deposits and inter corporate deposits	(2,120)	(2,206)
	Redemption/maturity of bank deposits and inter corporate deposits	3,732	3,432
	Interest received	222	218
	Proceeds from sale of current investments	10,413	11,763
	Purchase of current investments	(9,551)	(10,775)
	Net cash flow generated from/ (used in) investing activities	497	764
3	Cash flows from financing activities		
	Proceeds from issue of equity shares	8	4
	Proceeds/ (repayments) from short term borrowings, net	578	1
	Lease liabilities paid (including interest)	(275)	(268)
	Dividend paid	(505)	(504)
	Interest paid	(9)	(54)
	Net cash flow generated from/ (used in) financing activities	(203)	(821)
4	Net increase/(decrease) in cash and cash equivalents (1+2+3)	(1,138)	(508)
5	Effect of exchange difference on cash and cash equivalents held in foreign currency	51	109
6	Cash and cash equivalents at the beginning of the period/ year	2,286	3,671
7	Cash and cash equivalents at the end of the period/ year (4+5+6)	1,199	3,272
8	Components of cash and cash equivalents as at the end of the period/ year		
	Balances with banks	1,199	3,272
	Total cash and cash equivalents	1,199	3,272

STATEMENT OF UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026							
(Rs. in million, except per share data)							
Sl. No.	Particulars	3 months ended 30 September 2026	Preceding 3 months ended 30 June 2026	Corresponding 3 months ended in the previous year 30 September 2025	Year to date figures for the current period ended 30 September 2026	Year to date figures for the previous period ended 30 September 2025	Previous year ended 31 March 2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Income						
	a) Revenue from operations	7,779	6,630	8,301	14,409	16,294	34,238
	b) Other Income	275	248	142	523	308	669
	Total Income	8,054	6,878	8,443	14,932	16,602	34,907
2	Expenses						
	a) Cost of chemicals, reagents and consumables consumed	1,872	1,585	2,012	3,457	4,242	8,243
	b) Changes in inventories of finished goods and work-in-progress	(42)	(48)	110	(90)	(109)	74
	c) Employee benefits expense	2,280	2,143	2,330	4,423	4,533	9,337
	d) Finance costs	41	41	74	82	133	260
	e) Depreciation and amortisation expense	951	956	1,001	1,907	1,947	3,871
	f) Other expenses	1,597	1,686	1,940	3,283	3,990	7,795
	g) Foreign exchange fluctuation loss, net	598	480	134	1,078	182	643
	Total expenses	7,297	6,843	7,601	14,140	14,918	30,223
3	Profit before tax and exceptional items (1-2)	757	35	842	792	1,684	4,684
4	Exceptional Items, net gain/ (loss) [refer note 6 & 7]	(67)	(135)	-	(202)	-	(732)
5	Profit before tax (3-4)	690	(100)	842	590	1,684	3,952
6	Tax expense						
	Current tax	94	-	130	94	288	681
	Deferred tax	109	(79)	50	30	(6)	222
	Total tax expense	203	(79)	180	124	282	903
7	Profit for the period / year (5-6)	487	(21)	662	466	1,402	3,049
8	Other comprehensive income						
	(A) (i) Items that will not be reclassified to profit or (loss)	(27)	(7)	(41)	(34)	(39)	(53)
	(ii) Income tax relating to items that will not be reclassified to profit or (loss)	6	2	11	8	10	13
	(B) (i) Items that will be reclassified to profit or (loss)	46	397	(2,011)	443	(1,733)	(3,027)
	(ii) Income tax relating to items that will be reclassified to profit or (loss)	(9)	(113)	541	(122)	456	752
	Other comprehensive income for the period / year, net of taxes	16	279	(1,500)	295	(1,306)	(2,315)
9	Total comprehensive income for the period / year (7+8)	503	258	(838)	761	96	734
10	Paid-up equity share capital (Face value of Rs.10 each) [refer note 4]	4,037	4,037	4,029	4,037	4,029	4,029
11	Reserves excluding revaluation reserves as per balance sheet i.e. 'Other Equity'						43,009
12	Earnings per share (of Rs.10 each)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(not annualised)	(annualised)
	a) Basic	1.21	(0.05)	1.65	1.16	3.49	7.58
	b) Diluted	1.21	(0.05)	1.65	1.16	3.49	7.57
	See accompanying notes to the financial results						

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STANDALONE STATEMENT OF ASSETS AND LIABILITIES		
Particulars	(Rs. in Million)	
	As at 30 September 2026	As at 31 March 2026
	(Unaudited)	(Audited)
ASSETS		
Non-current assets		
Property, plant and equipment	21,613	22,440
Capital work-in-progress [refer note 5]	5,558	5,359
Right-of-use assets	1,659	1,765
Investment property	209	315
Other intangible assets	401	350
Intangible assets under development	47	53
Financial assets		
(i) Investments	10,344	11,202
(ii) Derivative assets	248	317
(iii) Other financial assets	1,861	2,999
Deferred tax assets (net)	698	842
Income tax assets (net)	1,372	977
Other non-current assets	166	91
Total non-current assets	44,176	46,710
Current assets		
Inventories	1,584	1,369
Financial assets		
(i) Investments	3,656	4,495
(ii) Trade receivables	3,394	4,325
(iii) Cash and cash equivalents	694	1,205
(iv) Bank balances other than (iii) above	7	2,021
(v) Derivative assets	26	69
(vi) Other financial assets	6,769	4,238
Other current assets	1,220	1,078
Total current assets	17,350	18,800
Total assets	61,526	65,510
EQUITY AND LIABILITIES		
Equity		
Equity share capital	4,037	4,029
Other equity	43,271	43,009
Total equity	47,308	47,038
Liabilities		
Non-current liabilities		
Financial liabilities		
(i) Lease liabilities	1,851	1,906
(ii) Derivative liabilities	196	488
(iii) Other financial liabilities	2	1
Provisions	-	177
Other non-current liabilities	1,777	1,979
Total non-current liabilities	3,826	4,551
Current liabilities		
Financial liabilities		
(i) Lease liabilities	109	102
(ii) Trade payables		
total outstanding dues of micro and small enterprises	549	500
total outstanding dues of creditors other than micro and small enterprises	2,240	2,056
(iii) Derivative liabilities	1,035	1,089
(iv) Other financial liabilities	1,092	1,419
Provisions	749	1,005
Current tax liabilities (net)	13	18
Other current liabilities	4,605	7,732
Total current liabilities	10,392	13,921
Total equity and liabilities	61,526	65,510

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore - 560099

STANDALONE STATEMENT OF CASH FLOWS			
		(Rs. in Million)	
Sl. No.	Particulars	Six months ended 30 September 2026	Six months ended 30 September 2025
		(Unaudited)	(Unaudited)
1	Cash flows from operating activities		
	Profit for the year	466	1,402
	<u>Adjustments to reconcile profit after tax to net cash flows:</u>		
	Depreciation and amortisation expense	1,907	1,947
	(Gain)/loss on disposal of property, plant and equipment (net)	(25)	11
	Impairment allowances of doubtful trade receivables	53	(3)
	Bad debts written off	-	278
	Provision for doubtful advances to supplier	(7)	
	Share-based payment expenses (net)	4	173
	Interest expense	82	133
	Unrealised foreign exchange (gain)/loss	(15)	-
	Net gain on sale of current investments	(59)	(43)
	Interest on Income tax refund	(51)	-
	Interest income	(412)	(265)
	Tax expenses	124	282
	Operating profit before working capital changes	2,067	3,915
	Movements in working capital		
	Decrease/ (increase) in inventories	(215)	(340)
	Decrease/ (increase) in trade receivables	867	(376)
	Decrease/ (increase) in financial and other assets	(149)	(829)
	Increase/ (decrease) in trade payables, provisions, financial and other liabilities	(3,681)	(2,727)
	Cash generated from/ (used in) operations	(1,111)	(357)
	Income taxes paid (net of refunds)	(443)	(343)
	Net cash flow generated from/ (used in) operating activities	(1,554)	(700)
2	Cash flows from investing activities		
	Purchase of property, plant and equipment including investment properties and capital work-in progress	(1,269)	(1,362)
	Proceeds from sale of property plant and equipments	28	1
	Purchase of intangible assets including intangible assets under development	(102)	(116)
	Investment in equity shares	(25)	-
	Investment in bank deposits and inter corporate deposits	(2,120)	(2,207)
	Redemption/maturity of bank deposits and inter corporate deposits	3,724	3,431
	Interest received	220	202
	Proceeds from sale of current investments	9,586	10,984
	Purchase of current investments	(8,406)	(9,979)
	Net cash flow generated from/ (used in) investing activities	1,636	954
3	Cash flows from financing activities		
	Proceed from issue of equity shares	8	4
	Lease liabilities paid (including interest)	(131)	(128)
	Dividend paid	(505)	(504)
	Interest paid	-	(47)
	Net cash flow generated from / (used in) financing activities	(628)	(675)
4	Net increase/(decrease) in cash and cash equivalents (1+2+3)	(546)	(421)
5	Effect of exchange difference on cash and cash equivalents held in foreign currency	35	93
6	Cash and cash equivalents at the beginning of the period/ year	1,205	2,335
7	Cash and cash equivalents at the end of the period/ year (4+5+6)	694	2,007
8	Components of cash and cash equivalents as at the end of the period/ year		
	Balances with banks	694	2,007
	Total cash and cash equivalents	694	2,007

SYNGENE INTERNATIONAL LIMITED

CIN : L85110KA1993PLC014937 Website: www.syngeneintl.com

Registered office: Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area IV Phase, Jigani Link Road, Bommasandra, Bangalore -

Notes :

- 1 The accompanying statement of unaudited standalone and consolidated financial results ("the Statements") of Syngene International Limited ('the Company') have been prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards (IND-AS) prescribed under section 133 of the Companies Act, 2013, as amended, read with the relevant rules issued thereunder. In terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, as amended, the Statements have been reviewed by the Audit Committee at their meeting held on 27 October 2026 and approved by the Board of Directors of the Company at their meeting held on 27 October 2026. The above Statements have been subjected to a limited review by the statutory auditors of the Company.
- 2 The consolidated financial results include the financial results of the Company - Syngene International Limited (including Syngene Employees Welfare Trust) and the financial results of the following subsidiaries:
 - i. Syngene USA Inc.
 - ii. Syngene Scientific Solutions Limited
 - iii. Syngene Manufacturing Solutions Limited (In the process of liquidation from 15 June 2026)The Company and the Subsidiaries are collectively referred to as 'the Group'.
- 3 The Group operates in a single segment of providing Contract Research and Manufacturing Services.
- 4 On 29 April 2026, the Board of Directors of the Company have approved an allotment of 729,727 equity shares of Rs. 10/- (Rupees Ten each) of the Company to Syngene Employees Welfare Trust at face value for the purpose of implementation of the Syngene Long Term Incentive Performance Share Plan 2023.
- 5 During the quarter ended 31 March 2025, Syngene USA Inc. (wholly-owned subsidiary of the Company) acquired biologics site in the USA from Emergent Manufacturing Operations Baltimore, LLC. The transaction was accounted for as an 'asset acquisition' under Ind AS 103 during the year ended 31 March 2025. As at 30 September 2026, Rs 4,876 million (31 March 2026: Rs 4,047 million) is accumulated in capital work in progress including Rs 1,246 million (31 March 2026: Rs 585 million) of pre-operative costs as management is of the view the same is eligible for capitalisation.
- 6 Effective 21 November 2025, the Government of India consolidated multiple existing labour legislations into a unified framework comprising four Labour Codes collectively referred as the 'New Labour Codes'. The Group assessed and disclosed the incremental impact of these changes based on the best information, which resulted in increase in gratuity liability by Rs 429 million and Rs 463 million in the standalone and consolidated financial results respectively, and the same was recognised as "exceptional Items" for the year ended 31 March 2026.
The Group continues to monitor the developments pertaining to the implementation of the New Labour Codes, including related rules thereto and would continue to assess the accounting implications basis such developments/ guidance as may be needed.
- 7 During the year ended 31 March 2026, quarter ended 30 June 2026, and 30 September 2026 termination benefits amounting to Rs. 303 million, Rs 135 million and Rs 67 million respectively were extended to employees in accordance with the approved policy. Considering the nature, significance and frequency of these benefits, these are disclosed as "exceptional items" in the standalone and consolidated financial results.
- 8 During the quarter ended 30 June 2026, the Board of Directors of Syngene International Limited approved the voluntary liquidation of its wholly owned subsidiary, Syngene Manufacturing Limited (SMSL), pursuant to a Board Resolution dated 18 May 2026. Subsequently, the shareholders approved the proposal for liquidation on 15 June 2026.
As at 30 September 2026, the liquidation process is ongoing and is subject to the completion of the applicable statutory, regulatory and legal formalities.
- 9 The figures of the previous periods/year end have been regrouped/ reclassified, wherever necessary.

For and on behalf of the Board of Directors of
Syngene International Limited

KIRAN
MAZUMDAR
AR SHAW

Digitally signed by
KIRAN MAZUMDAR
SHAW
Date: 2026.10.27
18:24:32 +05'30'

Kiran Mazumdar Shaw
Chairperson

Place :- Bangalore

Date :- 27 October 2026

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Syngene International Limited**

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Syngene International Limited (the "Holding Company") and its subsidiaries (the Holding Company and its subsidiaries together referred to as "the Group") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Holding Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Holding Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the Master Circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entities:
 - (i) Syngene International Limited
 - (ii) Syngene Scientific Solutions Limited
 - (iii) Syngene USA Inc.
 - (iv) Syngene Manufacturing Solutions Limited (under liquidation w.e.f. June 15, 2026)
 - (v) Syngene Employees Welfare Trust
5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S.R. BATLIBOI & ASSOCIATES LLP

Chartered Accountants

6. The comparative Ind AS financial information of the Group, for the corresponding quarter and six months period ended September 30, 2025, and preceding quarter ended June 30, 2026, included in these consolidated Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS consolidated financial statements of the Group for the year ended March 31, 2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those consolidated financial information on November 05, 2025, July 29, 2026 and April 29, 2026 respectively.

For S.R. Batliboi & Associates LLP

Chartered Accountants

ICAI Firm registration number: 101049W/E300004

SANDEEP
KARNANI

Digitally signed by
SANDEEP KARNANI
Date: 2026.10.27
18:33:37 +05'30'

per Sandeep Karnani

Partner

Membership No.: 061207

UDIN: 26061207SKBFNB6677

Place: Bengaluru

Date: October 27, 2026

Independent Auditor's Review Report on the Quarterly and Year to Date Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended**Review Report to
The Board of Directors
Syngene International Limited**

1. We have reviewed the accompanying statement of unaudited standalone financial results of Syngene International Limited (the "Company") for the quarter ended September 30, 2026 and year to date from April 01, 2026 to September 30, 2026 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. The Company's Management is responsible for the preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Statement has been approved by the Company's Board of Directors. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
5. The comparative Ind AS financial information of the Company for the corresponding quarter and six months period ended September 30, 2025 and preceding quarter ended June 30, 2026, included in these standalone Ind AS financial results, were reviewed by the predecessor auditor and the Ind AS financial statements of the Company for the year ended March 31, 2026, were audited by predecessor auditor who expressed an unmodified conclusion and unmodified opinion on those financial information on November 05, 2025, July 29, 2026 and April 29, 2026 respectively.

For S.R. Batliboi & Associates LLP
Chartered Accountants
ICAI Firm registration number: 101049W/E300004

**SANDEEP
KARNANI**

Digitally signed by SANDEEP
KARNANI
Date: 2026.10.27 18:32:46
+05'30'

Per Sandeep Karnani
Partner
Membership No.: 061207

UDIN: 26061207MEXTVR3274

Place: Bengaluru
Date: October 27, 2026